



Regd. Office : 'Zydus Tower', Satellite Cross Roads, Ahmedabad 380 015. India. Phone : +91-79-2686 8100 (20 Lines) Fax : +91-79-2686 2368 www.zyduscadila.com CIN:L24230GJ1995PLC025878

January 7, 2017

BSE Limited	National Stock Exchange of India Limited
1 st Floor, P J Towers,	Exchange Plaza, 5 th Floor,
Dalal Street	Plot No. C/1, G Block,
<u> Mumbai – 400 001</u>	Bandra – Kurla Compelx, bandra [East],
	<u> Mumbai – 400 051</u>
Kind Attn.: Mr. Sanjay Golecha/	Kind Attn.: Famroze Pochara
Mr. Gopalkrishnan	Asst. Vice President
Date: January 7, 2017	
Re.: JP Morgan Investor Conference	

Dear Sir / Madam,

Pursuant to Regulation 30 of SEBI [Listing Obligations and Disclosure Requirement] Regulations, 2015, we hereby inform that the Company is going to participate in JP Morgan Investor Conference scheduled to be held on January 9, 2017 to January 12, 2017 in US. We enclose herewith the presentation to be made to the investors for your ready reference.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully, For, CADILA HEALTHCARE LIMITED

HC **UPEN H. SHAH** AHMEDABAS COMPANY SECRETARY 4 Encl.: As above



Cadila Healthcare Limited Investor Presentation November 2016









Well integrated pharma player with global footprints



Track Record of Value Creation...



* Market Capitalisation is calculated by applying the closing price of the financial year.



Key Financial Numbers – H1 2016-17

Consolidated (Rs. Mio.)	Amount	Gr.%	Segment-wise Gross Sales *
Total Income from Operations	47,366	-1.8%	
EBIDT	10,399	-12.5%	India Fo <u>rm.,</u> 35% Alliances,1%
EBIDT % to Income from Ops.	22.0%		
Profit before tax	8,752	-17.7%	APIs, 4% Animal Health, 5%
PBT % to Income from Ops.	18.5%		Wellness, US Form. 5%
Net Profit	6,938	-25.8%	EU Form.,
Net Profit % to Income from Ops.	14.6%		EM Form., Latam Form., 5% 3%
R&D Spend % to Income from Ops.	6.6%		
Debt net of cash (as at 30-Sep-16)	18,363		Other BusinessesForm. Business - Key Markets, 82% of total,
Capex (H1 2016-17)	7,022		Up 6% y-o-y Down 1% y-o-y
dedicated life			* Gross Sales = Rs. 46,491 Mio.

US formulations – 9th largest generic player (based on scripts)

Market size*	: ~\$ 67 bn
Market growth*	: -1%
Zydus size**	: ~ \$ 614 mn
Zydus growth**	: 10%

24% CAGR in Sales (Last 5 years)



Aspirations

- Be amongst the top 10 generic cos. in US with continued strong focus on customer needs
- One of the significant contributors to revenues and profits

Strengths to be leveraged


- Sale of generic oral solids and injectable products
- Strong sales and marketing base long-term relationships with large whole-sellers & retail chains
- Cost efficient manufacturing and supply chain
- Robust regulatory pipeline 275+ ANDA fillings, 105+ approvals
- Alliance with innovator pharma companies for sale of authorized generics (AGs)
- 75+ products launched so far (incl. 9 AGs)
- Among top 3 for ~3/4th of the products marketed in US
- Ranked 9th among US generic companies based on scripts (Source : IMS MAT September,2016 Report).





US formulations – strong product pipeline

Growing Focus on Complex Generics



India formulations – 4th largest player

Aspirations

- Leadership in respiratory, female healthcare and pain mgt. area, among top 5 players in GI, CVS and derma
- Continue to be one of the significant contributors to revenues and profits


Strengths to be leveraged

- One of the largest market players with leading positions in key therapy areas
- Strong brand equity : 16 brands among top 300 in India
- New product launches : 35 during H1 2016-17 (incl. line extensions), with 8 First-in-India
- Alliances with global players for new product launches Sovihep (Sofosbuvir)
- First company in the world, which launched
 - Lipaglyn® (Saroglitazar in Q2 FY 14), the first NCE discovered and developed by an Indian company
 - Exemptia® (Q3 FY 15), world's first biosimilar of Adalimumab



Market size*	: Rs. 1030 bn+
Market growth*	: 11%
Zydus size**	: Rs. 43.5 bn+
Market Share**	: 4.2%
Zydus growth**	: 9%

Key therapies : ~66% of total sales#



CVS = Cardiovasculars GI = Gastro Intestinals Respi = Respiratory FHC = Female Healthcare Derma = Dermatology Als = Anti Infectives Neutra = Neutraceuticals Neuro = Neurologicals



* All market related information sourced from AWACS MAT-Sep-16

** Zydus numbers including Biochem as reported by AWACS MAT-Sep-16 # Sales of branded formulations in India for FY 2015-16.

Latin America formulations

Aspirations : To establish strong base with aggressive product launches						
Brazil	 Presence in branded generics and generic generics segments with a continued focus on brand building initiatives 					
Mkt. Size* : ~ BR\$ 83 bn . Mkt. Gr. : ~ 5%	 Robust product pipeline from India - 96 filings, 45 approvals Focused segments (Branded) – female healthcare, hepatology, CNS, CVS, Nutraceuticals and Pain Mgt. Product launches : 25+ branded, 20+ generic generics 					
Mexico	 Focus therapy area (Branded) – CNS 					
Mkt. Size* : ~ US\$ 8 bn . Mkt. Gr. : ~ -8 %	 Building product pipeline from India – 40+ filings and 35+ approvals so far Commenced commercial operations in 2013 with launch of first product from India 					
In overall Latin America : Zydus Size** : Rs. 2,177 mn Zydus growth** : 24% in constant currency	 Launched 20 products in the market so far. 					



Emerging Markets formulations

Market size* : ~ **\$ 13 bn** Market growth* : ~ **12-13%** Zydus size** : **Rs. 4,760 mn** Zydus growth** : **17%**

Aspirations

 To strengthen the position in different markets of Asia and Africa

Strengths to be leveraged



- Operations in different markets of Asia Pacific and Africa and Middle East region with leadership position in several of these markets.
- Focus on brand building initiatives and strengthening branded generics portfolio to ensure sustainable growth in topline and bottomline.
- Increased product development activities supported by strong regulatory teams.
- Commenced biosimilars business in emerging markets by launching the first biosimilar viz. Pegihep in FY 2015-16.





* Approx. numbers as per EvaluatePharma for emerging markets ** Zydus numbers as reported in books for FY 2015-16

Other businesses (1/2)

EU formulations	Aspirations : To be a relevant player in generic markets of France and Spain
Mkt. Size* : ~Euro 5.4 bn (France + Spain Gx) Mkt. Gr. : 4% Zydus Size **: Rs. 2,956 mn Zydus Gr. : -12%	 Among top 10 in France, among top 20 in Spain Expansion through new products : launched ~150 molecules in France and ~110 molecules in Spain so far (incl. several 'Day 1') Leveraging India cost advantage : 200+ new products and 65+ site transfer filings so far, >50% of sales supplied from India
Consumer Wellness	Aspirations : To create niches in wellness space through innovation
Zydus Size **: Rs. 4,570 mn Zydus Gr. : 3%	 Leadership in sugar substitutes (~94% market share) and in couple of subcategories viz. scrub and peel-off of skin care products. Continued thrust on different marketing initiatives to grow the categories and market share of different brands.



* Approx. numbers as per GERS and IMS Report for Europe as per MAT September,16 data. ** Zydus numbers as reported in books for FY 2015-16



Other Businesses (2/2)

Animal Health	Aspirations : To be a comprehensive, global animal healthcare provider						
Zydus Size *: Rs. 3,169 mn Zydus Gr. : 3%	 One of India's leading animal healthcare players. Acquired select brands and manufacturing operations in India from Zoetis, a global animal healthcare company so as to expand business in India. Presence in key markets across Europe, South America, Asia and Africa through Bremer Pharma, Germany. 						

APIs	Aspirations : To be a 'reliable' service provider to customers
Zydus Size *: Rs. 3,647 mn Zydus Gr. :-2%	 Backward integration capabilities to meet captive API requirements. Operations in India, US and select markets of Europe, Latin America, Asia Pacific and Middle East regions. Continuous endeavour to improve service levels by improving cost competitiveness and continuous process improvement.




Joint Ventures and Alliances – leveraging strengths

Aspirations : Value creation through win-win alliances and be a partner of choice

Zydus Takeda JV	Zydus Hospira JV			
 State-of-the-art mfg. facility for APIs of Takeda Expanded the facility to manufacture complex high-end APIs Commercial supply of 10 products (incl. 2 for validation) 	 State-of-the-art cytotoxic facility approved by leading authorities like MHRA, USFDA, TGA, Health Canada Commercial supply of 12 products for EU market and 8 products for US market 			
Bayer Zydus JV	Alliances with other partners			
 Operates in female healthcare, metabolic disorders, diagnostic imaging, CVS, diabetes and oncology segments in India Leveraging strengths of Bayer's optimized product portfolio and Zydus' marketing and distribution capabilities JV scope covers launch of innovator products of Bayer 	 26 ANDAs filed for various partners, 14 approved,11 commercialised. Received the first NDA approval from US FDA which was filed on behalf of a partner. Commercial supply of 14 products so far under the out-licensing deal with Abbott 			



Strong focus on R&D



Biosimilars and Vaccines – emerging businesses

Aspirations : Leverage technological edge to unlock substantial value and create pillars for future growth.

Strengths to be leveraged **Biosimilar pipeline** Regulatory Mktg. Pre-**Biosimilars** Clinical Process Product Cloning Clinical Permissio Authori-No Indication Devp. Devp. Devp. sation Dedicated facilities for bulk and G-CSF Oncology finished formulations Peq G-CSF 2 Oncology LAUNCHED 70+ experienced scientists IFN α-2b Infectious diseases 3 **Teriparatide** 4 Osteoporosis (in India) Strong pipeline: 15 biosimilars 5 Adalimumab Inflammation and 6 novel products 6 Trastuzumab Oncology 7 Peg IFN α-2b Infectious diseases Launched in India and EM (Myanmar) Strong IP position either through EPO Oncology/Nephrolog 8 own patent or non-infringing 9 MAB 1 Oncology/RA MAB 2 processes 10 Oncology 11 Prod 1 AMI Vaccines Prod 2 12 Fertility Dedicated R&D and mfg. facilities MAB 3 13 Rabies 14 PEG-EPO Nephrology 70+ experienced scientists Oncology 15 Prod 3 MAB 4 10 vaccines under different 16 Osteoporosis MAB 5 17 Oncology stages of clinical development 18 Prod 4 Oncology Received MA for 6 vaccines in Prod 5 19 Oncology Prod 6 Oncology 20 India, 3 vaccines submitted for Complement Prod 7 MA 21 mediated disease





NCE Research

Aspirations : Add more NCEs in pipeline to drive towards becoming a research based pharma co. by 2020

Key strengths


- State-of-the art research facility
- Capability of target identification to pre-clinical research / early clinical development
- ~275 scientists dedicated for NCE research
- Strong scientific advisory board comprising of world's renowned scientists, academicians and clinicians



	NCE Pipeline									
Project	Target	Indication	Drug Discovery	Lead optimi- saiton	Pre- clinical Develop- ment	IND	Phase I	Phase II	Phase III	NDA
Saro- glitazar	PPAR-α,γ	Dyslipidemia	Firs	t glitazar to	be approved	I in the wor	ld. Launche	d in India a	s "LIPAGL)	(N "
Saro- glitazar	PPAR-α,γ	Hypertrigly- ceridemia	Firs	t glitazar to	be approved	in the wor	ld. Launche	d in India a	s "LIPAGL	(N "
Saro- glitazar	PPAR-α,γ	Lipodystrophy								
Saro- glitazar	PPAR-α,γ	Nonalcoholic Steatohepatitis								
Saro- glitazar	PPAR-α,γ	Type 2 Diabetes								
Saro- glitazar	PPAR-α,γ	Hypertrigly- ceridemia		Clinical	trials goinę	g on in US				
Saro- glitazar	PPAR-α,γ	Nonalcoholic Steatohepatitis		Clinical	trials goine	g on in US				
ZYH7	PPAR-α	Dyslipidemia								
ZYDPLA1	DPP-IV inhibitor	Type 2 Diabetes		Clinical tr	ials going	on in US				
ZYAN1	HIF - inhibitor	Anemia								<u> </u>
ZYTP1	PARP - inhibitor	Oncology								97

NCE Dinolino

World class infrastructure to support ZyNext journey



Total facilities inspected by US FDA - 11 (Formulations - 9, APIs - 2)



Capabilities across delivery platforms – Oral Solids, Controlled Substances, Injectables, Topicals, Lyophilized Injectable, Sprays and Transdermals

Key strategies for ZyNext journey

Strong execution focus for the U.S. market; drive growth with continuous focus on product launches

2

3

Focus on difficult to develop and manufacture and specialty products to improve margins

In India, focus on high growth Therapeutic Areas, outperform the domestic market and improve operational efficiency through increasing sales force productivity and technological advancement

4 Leverage strong platform of biosimilars and vaccines business

Select inorganic growth to expand in India, U.S. and Emerging Markets, acquire capability platforms and move forward in value chain on specialty and branded business



5



Thank You.

Safe Harbour Statement

This presentation may include certain "forward looking statements", based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the company does not guarantee realization of these statements. The Company also disclaims any obligation to revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Cadila Healthcare Ltd.



www.zyduscadila.com

